» Articles » PMID: 35619184

Application and Prospect of Targeting Innate Immune Sensors in the Treatment of Autoimmune Diseases

Overview
Journal Cell Biosci
Publisher Biomed Central
Specialty Biology
Date 2022 May 26
PMID 35619184
Authors
Affiliations
Soon will be listed here.
Abstract

Dysregulation of auto-reactive T cells and autoantibody-producing B cells and excessive inflammation are responsible for the occurrence and development of autoimmune diseases. The suppression of autoreactive T cell activation and autoantibody production, as well as inhibition of inflammatory cytokine production have been utilized to ameliorate autoimmune disease symptoms. However, the existing treatment strategies are not sufficient to cure autoimmune diseases since patients can quickly suffer a relapse following the end of treatments. Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), Nod-like receptors (NLRs), RIG-I like receptors (RLRs), C-type lectin receptors (CLRs) and various nucleic acid sensors, are expressed in both innate and adaptive immune cells and are involved in the development of autoimmune diseases. Here, we have summarized advances of PRRs signaling pathways, association between PRRs and autoimmune diseases, application of inhibitors targeting PRRs and the corresponding signaling molecules relevant to strategies targeting autoimmune diseases. This review emphasizes the roles of different PRRs in activating both innate and adaptive immunity, which can coordinate to trigger autoimmune responses. The review may also prompt the formulation of novel ideas for developing therapeutic strategies against autoimmune diseases by targeting PRRs-related signals.

Citing Articles

Decreased muscle strength in adjuvant-induced rheumatoid arthritis animal model: A relationship to behavioural assessments.

Ghouri M, Lateef M, Liaquat L, Zulfquar A, Saleem S, Zehra S Heliyon. 2024; 10(1):e23264.

PMID: 38163119 PMC: 10754872. DOI: 10.1016/j.heliyon.2023.e23264.


A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis.

Vebr M, Pomahacova R, Sykora J, Schwarz J Biomedicines. 2023; 11(12).

PMID: 38137450 PMC: 10740682. DOI: 10.3390/biomedicines11123229.


CXCR1 drives the pathogenesis of EAE and ARDS via boosting dendritic cells-dependent inflammation.

Zhuang W, Zhou J, Zhong L, Lv J, Zhong X, Liu G Cell Death Dis. 2023; 14(9):608.

PMID: 37709757 PMC: 10502121. DOI: 10.1038/s41419-023-06126-y.


Immunological Imbalances Associated with Epileptic Seizures in Type 2 Diabetes Mellitus.

Phoswa W, Mokgalaboni K Brain Sci. 2023; 13(5).

PMID: 37239204 PMC: 10216299. DOI: 10.3390/brainsci13050732.


Innate immunity and nonalcoholic fatty liver disease.

Kountouras J, Kazakos E, Kyrailidi F, Polyzos S, Zavos C, Arapoglou S Ann Gastroenterol. 2023; 36(3):244-256.

PMID: 37144011 PMC: 10152810. DOI: 10.20524/aog.2023.0793.


References
1.
He H, Lin B, Chen Y, Deng X, Jiang W, Zhou R . RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Cell Mol Immunol. 2021; 18(6):1425-1436. PMC: 8166941. DOI: 10.1038/s41423-021-00683-y. View

2.
Sun L, Liu W, Zhang L . The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis. J Immunol Res. 2019; 2019:1824624. PMC: 6877906. DOI: 10.1155/2019/1824624. View

3.
De Nardo D, Balka K, Cardona Gloria Y, Rao V, Latz E, Masters S . Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling. J Biol Chem. 2018; 293(39):15195-15207. PMC: 6166714. DOI: 10.1074/jbc.RA118.003314. View

4.
Kitai Y, Takeuchi O, Kawasaki T, Ori D, Sueyoshi T, Murase M . Negative regulation of melanoma differentiation-associated gene 5 (MDA5)-dependent antiviral innate immune responses by Arf-like protein 5B. J Biol Chem. 2014; 290(2):1269-80. PMC: 4294491. DOI: 10.1074/jbc.M114.611053. View

5.
de Koning H, Simon A, Zeeuwen P, Schalkwijk J . Pattern recognition receptors in immune disorders affecting the skin. J Innate Immun. 2012; 4(3):225-40. PMC: 6741553. DOI: 10.1159/000335900. View